Partnership is central to ReForma's development model
We collaborate with pharmaceutical companies, contract development and manufacturing organizations (CDMOs), device and technology innovators, clinical research organizations and specialist advisors to bring together the capabilities required to advance differentiated medicines efficiently. We keep the network deliberately small, because a reformulation program depends on the quality of two or three technical relationships rather than many.
PARTNERSHIPS
What ReForma brings
ReForma brings program selection and the target product profile; formulation and CMC strategy; the development plan; the regulatory route, agency dialogue and the filing; clinical bridging design and modeling support; and commercial assessment and the route to market.
What we look for in partners
We look for partners with real formulation or device depth in the relevant format, GMP manufacture and scale-up capability, quality systems that will support global registration, and an interest in a relationship rather than a single transaction.
Structures we are open to
Fee-for-service
Partner develops and supplies the product, while ReForma funds the programme, owns the rights and files the regulatory submission.
Co-development
Shared program selection, shared cost and shared upside.
Two-way
ReForma takes a partner's existing product into a new market.
Our collaboration model is flexible and built around shared development objectives and long-term value creation.
Investors
ReForma is advancing a focused portfolio of differentiated pharmaceutical development programs through a disciplined, milestone-driven model. We selectively evaluate strategic investment, federal and public-sector funding, and partnership opportunities aligned with the advancement of our portfolio.
Interested in partnering with ReForma? Contact our business development team.